Esperion Therapeutics
ESPR
ESPR was delisted on the 10th of July, 2026.
139 hedge funds and large institutions have $299M invested in Esperion Therapeutics in 2021 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 35 increasing their positions, 40 reducing their positions, and 25 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
8% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 25
2% less funds holding
Funds holding: 142 → 139 (-3)
13% less repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 40
12.73% less ownership
Funds ownership: 100.56% → 87.84% (-13%)
19% less call options, than puts
Call options by funds: $9.22M | Put options by funds: $11.4M
50% less capital invested
Capital invested by funds: $600M → $299M (-$300M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BNP Paribas Financial Markets
Paris,
France
|
+$3.69M |
| 2 |
Voloridge Investment Management
Jupiter,
Florida
|
+$2.79M |
| 3 |
HF
HRT Financial
New York
|
+$2.69M |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$2.32M |
| 5 |
Millennium Management
New York
|
+$2.19M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$24.4M |
| 2 |
BC
Boxer Capital
San Diego,
California
|
-$10.6M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$9.49M |
| 4 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$8.46M |
| 5 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$7.17M |
ESPR Hedge Fund Activity: Q3 2021 in Review
139 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Esperion Therapeutics (ESPR) for Q3 2021, worth a combined $299M — down 50% from $600M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of ESPR and 23 opened new positions — a net loss of 2 holders — while 40 trimmed existing stakes and 35 added.
The largest buyer was BNP Paribas Financial Markets, adding an estimated $3.69M. The largest seller was State Street, cutting an estimated $24.4M.
- 139 institutional investors held Esperion Therapeutics (ESPR) as of Q3 2021, down from 142 in Q2 2021.
- Funds reported $299M of Esperion Therapeutics stock for Q3 2021, down 50% quarter-over-quarter.
- 23 funds opened new Esperion Therapeutics positions in Q3 2021 and 25 closed out, a net change of -2 holders.
- The largest Esperion Therapeutics buyer in Q3 2021 was BNP Paribas Financial Markets, an estimated $3.69M added.
- The largest Esperion Therapeutics seller in Q3 2021 was State Street, an estimated $24.4M sold.
Based on aggregated 13F filings for Q3 2021.